Ertapenem-Induced Neurotoxicity: A Literature Review of Clinical Characteristics and Treatment Outcomes

References

• Hammond ML. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties. J Antimicrob Chemother. 2004;53(Suppl 2):ii7–9. doi:10.1093/jac/dkh203
   PubMed Web of Science ®Google Scholar
• Curran MP, Simpson D, Perry CM. Ertapenem: a review of its use in the management of bacterial infections. Drugs. 2003;63:1855–1878. doi:10.2165/00003495-200363170-00006
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, et al. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and Carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079–17. doi:10.1128/CMR.00079-17
   PubMed Web of Science ®Google Scholar
• Mistry GC, Majumdar AK, Swan S, et al. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. J Clin Pharmacol. 2006;46(10):1128–1138. doi:10.1177/0091270006291839
   PubMed Web of Science ®Google Scholar
• Jimenez-Cruz F, Jasovich A, Cajigas J, et al. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology. 2002;60(1):16–22. doi:10.1016/s0090-4295(02)01664-3
   PubMed Web of Science ®Google Scholar
• Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34(11):1460–1468. doi:10.1086/340348
   PubMed Web of Science ®Google Scholar
• Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, et al. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis. 2002;34(8):1076–1083. doi:10.1086/339543
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. INVANZ label. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22.Accessed May 2, 2023.
   Google Scholar
• European Medicines Agency. INVANZ-INN Ertapenem. Product information. Available from: https://www.ema.europa.eu/en/documents/product-information/invanz-epar-product-information_en.pdf. Accessed May 2, 2023.
   Google Scholar
• Teppler H, Gesser RM, Friedland IR, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother. 2004;53(Suppl 2):ii75–81. doi:10.1093/jac/dkh209
   PubMedGoogle Scholar
• Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother. 2007;8(2):237–256. doi:10.1517/14656566.8.2.237
   PubMed Web of Science ®Google Scholar
• Duquaine S, Kitchell E, Tate T, et al. Central nervous system toxicity associated with ertapenem use. Ann Pharmacother. 2011;45(1):e6. doi:10.1345/aph.1P528
   PubMedGoogle Scholar
• Deshayes S, Coquerel A, Verdon R. Neurological adverse effects attributable to β-lactam antibiotics: a literature review. Drug Saf. 2017;40(12):1171–1198. doi:10.1007/s40264-017-0578-2
   PubMed Web of Science ®Google Scholar
• Lee KH, Ueng YF, Wu CW, et al. The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients—case reports and literature reviews. J Clin Pharm Ther. 2015;40:240–244. doi:10.1111/jcpt.12239
   PubMed Web of Science ®Google Scholar
• El Nekidy WS, Elrefaei H, St John TJL, et al. Ertapenem neurotoxicity in hemodialysis patients-safe and effective dosing is still needed: a retrospective study and literature review. Ann Pharmacother. 2021;55(1):52–58. doi:10.1177/1060028020938059
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Shear NH, Lanctôt KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol. 1992;32(10):897–904. doi:10.1002/j.1552-4604.1992.tb04635.x
   PubMed Web of Science ®Google Scholar
• Sunagawa M, Matsumura H, Sumita Y, et al. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J Antibiot. 1995;48(5):408–416. doi:10.7164/antibiotics.48.408
   PubMed Web of Science ®Google Scholar
• Norby SR. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrob Chemother. 2000;45(1):5–7. doi:10.1093/jac/45.1.5
   PubMed Web of Science ®Google Scholar
• Miller AD, Ball AM, Bookstaver PB, et al. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011;31(4):408–423. doi:10.1592/phco.31.4.408
   PubMed Web of Science ®Google Scholar
• World Health Organization. VigiAccess TM. Available from: http://www.vigiaccess.org/. Accessed April 15, 2023.
   Google Scholar
• Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011;72(3):381–393. doi:10.1111/j.1365-2125.2011.03991.x
   PubMed Web of Science ®Google Scholar
• Schliamser SE, Cars O, Norrby SR. Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother. 1991;27(4):405–425. doi:10.1093/jac/27.4.405
   PubMed Web of Science ®Google Scholar
• Lee YC, Huang YJ, Hung MC, et al. Risk factors associated with the development of seizures among adult patients treated with ertapenem: a matched case-control study. PLoS One. 2017;12(7):e0182046. doi:10.1371/journal.pone.0182046
   PubMed Web of Science ®Google Scholar
• Saidel-Odes L, Borer A, Riesenberg K, et al. History of cerebrovascular events: a relative contraindication to ertapenem treatment. Clin Infect Dis. 2006;43(2):262–263. doi:10.1086/505304
   PubMed Web of Science ®Google Scholar
• Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy. 2007;27(8):1202–1205. doi:10.1592/phco.27.8.1202
   PubMed Web of Science ®Google Scholar
• Fica AE, Abusada NJ. Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency. Scand J Infect Dis. 2008;40(11–12):983–985. doi:10.1080/00365540802375570
   PubMed Web of Science ®Google Scholar
• Ong C, Chua AC, Tambyah PA, et al. Seizures associated with ertapenem. Int J Antimicrob Agents. 2008;31(3):290. doi:10.1016/j.ijantimicag.2007.08.024
   PubMed Web of Science ®Google Scholar
• Hsaiky LM, Salinitri FD, Wong J, et al. Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients. Nephrol Dial Transplant. 2019;34:1766–1772. doi:10.1093/ndt/gfy166
   PubMed Web of Science ®Google Scholar
• Wen MJ, Sung CC, Chau T, et al. Acute prolonged neurotoxicity associated with recommended doses of ertapenem in 2 patients with advanced renal failure. Clin Nephrol. 2013;80(6):474–478. doi:10.5414/CN107247
   PubMed Web of Science ®Google Scholar
• Cottagnoud P, Pfister M, Cottagnoud M, et al. Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother. 2003;47(6):1943–1947. doi:10.1128/AAC.47.6.1943-1947.2003
   PubMed Web of Science ®Google Scholar
• Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother. 2004;53(Suppl 2):ii23–8. doi:10.1093/jac/dkh205
   PubMed Web of Science ®Google Scholar
• Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother. 2002;46(11):3506–3511. doi:10.1128/AAC.46.11.3506-3511.2002
   PubMed Web of Science ®Google Scholar
• Patel UC, Fowler MA. Ertapenem-associated neurotoxicity in the spinal cord injury (SCI) population: a case series. J Spinal Cord Med. 2018;41(6):735–740. doi:10.1080/10790268.2017.1368960
   PubMed Web of Science ®Google Scholar
• Danés I, Pérez E, Pigrau C, et al. A case series of confusional states and other neurotoxic effects caused by ertapenem. Br J Clin Pharmacol. 2021;87(4):2140–2145. doi:10.1111/bcp.14582
   PubMed Web of Science ®Google Scholar
• Lin H, Chew ST. Status epilepticus and delirium associated with ertapenem in a very elderly patient with chronic kidney disease and silent ischaemic cerebrovascular disease. Drug Saf Case Rep. 2015;2(1):19. doi:10.1007/s40800-015-0021-5
   PubMedGoogle Scholar
• Kong V, Beckert L, Awunor-Renner C. A case of beta lactam-induced visual hallucination. N Z Med J. 2009;122(1298):76–77.
   PubMedGoogle Scholar